References

Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: A randomized clinical trial

10.1001/jama.2018.16773 · ExternalCitation · doi-reference

National trends in ambulatory oral anticoagulant use

10.1016/j.amjmed.2015.05.044 · ExternalCitation · doi-reference

Real-world effectiveness of lanadelumab in hereditary angioedema: multicountry INTEGRATED Observational Study

10.1016/j.jaip.2024.12.008 · ExternalCitation · doi-reference

Structures of factor XI and prekallikrein bound to domain 6 of high-molecular weight kininogen reveal alternate domain 6 conformations and exosites

10.1016/j.jtha.2023.03.042 · ExternalCitation · doi-reference

A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation

10.1016/j.thromres.2016.02.020 · ExternalCitation · doi-reference

Challenging clinical scenarios for therapeutic anticoagulation: a practical approach

10.1016/j.thromres.2022.08.015 · ExternalCitation · doi-reference

The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials

10.1055/s-0039-1692439 · ExternalCitation · doi-reference

Factor XII structure-function relationships

10.1055/s-0043-1769509 · ExternalCitation · doi-reference

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

10.1056/nejmoa1009638 · ExternalCitation · doi-reference

Inhibiting plasma kallikrein for hereditary angioedema prophylaxis

10.1056/nejmoa1605767 · ExternalCitation · doi-reference

Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema

10.1056/nejmoa1716995 · ExternalCitation · doi-reference

Antisense inhibition of prekallikrein to control hereditary angioedema

10.1056/nejmoa1915035 · ExternalCitation · doi-reference

Abelacimab for prevention of venous thromboembolism

10.1056/nejmoa2105872 · ExternalCitation · doi-reference

Inhibition of prekallikrein for hereditary angioedema

10.1056/nejmoa2109329 · ExternalCitation · doi-reference

Oral sebetralstat for on-demand treatment of hereditary angioedema attacks

10.1056/nejmoa2314192 · ExternalCitation · doi-reference

Efficacy and safety of donidalorsen for hereditary angioedema

10.1056/nejmoa2402478 · ExternalCitation · doi-reference

Hereditary angioedema

10.1056/nejmra1808012 · ExternalCitation · doi-reference

Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2

10.1074/jbc.274.36.25777 · ExternalCitation · doi-reference

Prekallikrein deficiency in man

10.1084/jem.138.6.1345 · ExternalCitation · doi-reference

Polyphosphate, platelets, and coagulation

10.1111/ijlh.12349 · ExternalCitation · doi-reference

Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice

10.1111/j.1538-7836.2006.02093.x · ExternalCitation · doi-reference

Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation

10.1111/j.1538-7836.2007.02792.x · ExternalCitation · doi-reference

The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities

10.1111/jth.13194 · ExternalCitation · doi-reference

Severe plasma prekallikrein deficiency: clinical characteristics, novel KLKB1 mutations, and estimated prevalence

10.1111/jth.14805 · ExternalCitation · doi-reference

Proteolytic activity of contact factor zymogens

10.1111/jth.15149 · ExternalCitation · doi-reference

Genes lost during the transition from land to water in cetaceans highlight genomic changes associated with aquatic adaptations

10.1126/sciadv.aaw6671 · ExternalCitation · doi-reference

Kallikrein cvleaves C3 and activates complement

10.1159/000484257 · ExternalCitation · doi-reference

Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait

10.1160/th11-10-0682 · ExternalCitation · doi-reference

Factor XI inhibition for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement: a phase 2 clinical trial

10.1161/atvbaha.123.319692 · ExternalCitation · doi-reference

Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding

10.1182/blood-2011-05-355248 · ExternalCitation · doi-reference

Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor

10.1182/blood-2014-01-550285 · ExternalCitation · doi-reference

Protease activity in single-chain prekallikrein

10.1182/blood.2019002224 · ExternalCitation · doi-reference

Biology of factor XI

10.1182/blood.2023020719 · ExternalCitation · doi-reference

The evolution of factor XI and the kallikrein-kinin system

10.1182/bloodadvances.2020002456 · ExternalCitation · doi-reference

Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains

10.1182/bloodadvances.2021005976 · ExternalCitation · doi-reference

Lack of plasma kallikrein-kinin system cascade in teleosts

10.1371/journal.pone.0081057 · ExternalCitation · doi-reference

Severe prekallikrein deficiency associated with low level of factor XII: A case report

10.30699/ijp.2021.131638.2463 · ExternalCitation · doi-reference

Plasma prekallikrein: its role in hereditary angioedema and health and disease

10.3389/fmed.2018.00003 · ExternalCitation · doi-reference

Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond

10.3389/fphys.2023.1188816 · ExternalCitation · doi-reference